Cyrano Therapeutics

There is currently no FDA-approved therapy for this increasingly prevalent and serious chronic sensory condition

Delray Beach, FL, October 12, 2023 – Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the development of treatments for smell loss, announced today that it has commenced enrollment in the Phase 2 FLAVOR trial,  a randomized, double-blinded, placebo-controlled, multi-dose clinical trial of CYR-064, its novel, soft-mist nasal-spray product candidate, for the treatment of post-viral hyposmia.  Post-viral hyposmia is an increasingly prevalent and serious chronic sensory condition for which there is currently no approved drug therapy.

“Hyposmia, along with the associated alterations in taste results in a significant reduction in quality of life, as this common and serious condition manifests as a loss of two of the five basic human senses,” stated Mas Takashima, MD FACS, Professor and Chairman of the Department of Otolaryngology – Head and Neck Surgery at Houston Methodist Hospital and the principal investigator for the FLAVOR trial.  “CYR-064 has the potential to become the first pharmaceutical product to restore the senses of smell and taste in patients with post-viral hyposmia and thereby address a major unmet clinical need.”

Cyrano expects to enroll approximately 150 subjects in the FLAVOR trial, which is designed to assess the local nasal safety, tolerability, and effectiveness of CYR-064 as compared to placebo in the treatment of post-viral hyposmia over a six-month period.  The FLAVOR trial is a multi-institutional prospective study being conducted at fifteen clinical sites in the United States. 

About Hyposmia

Hyposmia, including post-viral hyposmia, is an increasingly prevalent and serious chronic sensory condition for which there is no approved drug therapy [and limited treatment options].  Hyposmia causes significant impairment in quality of life for many sufferers.  Moreover, in older individuals, hyposmia is associated with an increased risk of cognitive impairment and mortality. .  Prior to the COVID-19 pandemic, an estimated 8 million individuals in the U.S. and Europe suffered from long-term post-viral hyposmia.  The COVID-19 pandemic has resulted in dramatically increased prevalence, with an estimated 40 million individuals in the U.S. and Europe currently suffering from long-term post-viral hyposmia. 

About Cyrano Therapeutics

Cyrano Therapeutics, Inc. is a private, venture-backed, clinical-stage regenerative medicine company.  Since our inception, we have been working diligently to develop therapies for people struggling with the loss of smell and taste.  For more information, please visit